RJA
LBPH

Raymond James & Associates’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History

Raymond James & Associates’s Portfolio LBPH Stock Details LBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$407K Buy
+12,200
New +$420K ﹤0.01% 3225

Other funds holding LBPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Raymond James & Associates's LBPH Position: Q3 2024 in Review

Raymond James & Associates opened a new position in Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q3 2024: 12,200 shares worth $407K. The stake represents ﹤0.01% of the portfolio and ranks #3225 among its holdings.

125 funds tracked by Wall St. Rank hold LBPH as of Q3 2024.

  • Raymond James & Associates held 12,200 shares of Longboard Pharmaceuticals, Inc. Common Stock worth $407K as of Q3 2024.
  • Longboard Pharmaceuticals, Inc. Common Stock was a new Raymond James & Associates position in Q3 2024.
  • Longboard Pharmaceuticals, Inc. Common Stock made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3225 holding.
  • 125 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.